Identity recordChina-approved medicine and active clinical program
What Mazdutide resolves to
Mazdutide has NMPA approvals in China for chronic weight management and glycemic control in adults with type 2 diabetes. Those China-specific approvals do not establish FDA approval, authorization in another country, or the identity and authority of an online seller.
- Evidence lane
- Clinical pipeline profile
- Current record
- China approvals active; Phase 3 and indication-expansion studies continue
- Checked
- July 22, 2026
IBI362LY3305677GLP-1/glucagon dual agonist
Destination recordPeptide-specific SAHPRA warning
What South Africa still has to prove
A South Africa guide to checking peptide offers against SAHPRA's current public warning, registered-medicine directory, and licensed-establishment records.
- Comparison mode
- ZAR / SAHPRA product and establishment records
- Price coverage
- No qualified South Africa seller table
- Guide updated
- July 18, 2026